In a report released today, Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Halozyme (HALO – Research Report), with a price target of $68.00. Mitchell Kapoor has given
In a report released today, Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Halozyme (HALO – Research Report), with a price target of $68.00. Mitchell Kapoor has given
In a report released today, Jason Butler from JMP Securities reiterated a Buy rating on Halozyme (HALO – Research Report), with a price target of $73.00. Jason Butler’s rating is
Analysts fell to the sidelines weighing in on Halozyme (HALO – Research Report), Bluebird Bio (BLUE – Research Report) and Spruce Biosciences (SPRB – Research Report) with neutral ratings, indicating that the experts are neither bullish nor bearish on the stocks.
Halozyme (HALO)
In a report issued on November 14, David Risinger from Leerink Partners maintained a Hold rating on Halozyme, with a price target of $136.00. The company’s shares closed last Monday at $42.57.
According to TipRanks.com, Risinger is a 5-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Halozyme with a $72.38 average price target, which is a 58.5% upside from current levels. In a report issued on November 4, Piper Sandler also maintained a Hold rating on the stock with a $52.00 price target.
See today’s best-performing stocks on TipRanks >>
Bluebird Bio (BLUE)
Leerink Partners analyst Mani Foroohar maintained a Hold rating on Bluebird Bio on November 14 and set a price target of $1.00. The company’s shares closed last Monday at $0.33, close to its 52-week low of $0.32.
According to TipRanks.com, Foroohar is ranked 0 out of 5 stars with an average return of
Currently, the analyst consensus on Bluebird Bio is a Hold with an average price target of $2.30, representing a 609.7% upside. In a report issued on November 15, Bank of America Securities also downgraded the stock to Hold with a $0.50 price target.
Spruce Biosciences (SPRB)
Leerink Partners analyst Joseph Schwartz maintained a Hold rating on Spruce Biosciences on November 14 and set a price target of $2.00. The company’s shares closed last Monday at $0.47, close to its 52-week low of $0.41.
According to TipRanks.com, Schwartz is a 5-star analyst with an average return of
Currently, the analyst consensus on Spruce Biosciences is a Moderate Buy with an average price target of $2.33, representing a 377.9% upside. In a report issued on November 11, RBC Capital also maintained a Hold rating on the stock with a $2.00 price target.
Read More on HALO:
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1. STOCK NEWS: Spirit Airlines (SAVE) has entered into Chapter 11 bankruptcy
Halozyme Therapeutics (HALO) provided an update on its non-binding proposal to acquire Evotec SE (EVO) for EUR 11.00 per share in cash, implying a fully diluted equity value of EUR